LENZ Therapeutics, Inc.
(NASDAQ:LENZ) on Wednesday announced an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd.
The agreement marks LENZ's latest effort to expand the commercial reach of its recently approved eye drop therapy beyond the U.S. market.
Read Also: New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug Arrotex Secures Exclusive Commercialization Rights Arrotex will receive exclusive rights to register and commercialize VIZZ (aceclidine ophthalmic solution) for the treatment of presbyopia in Australia and New Zealand.
In return, LENZ will receive an upfront payment from Arrotex, along with a significant share of the gross margin generated from product sales.
